- Our Doctors
- Dr Victoria Woodcock
Dr Victoria Woodcock
BSc(Hons), MBChB, PGCert, DPhil (Oxon), MRCP, Consultant Medical Oncologist
Languages spoken
English
Expert in
Chemotherapy, targeted therapies and immunotherapies for the treatment of colorectal cancer
Interested in
Dr Woodcock has extensive experience in the use of chemotherapy, immunotherapy, and targeted therapies. Her main research interest lies in the development of new cancer treatments that enhance the immune response to tumours.
Overview
Centres
Specialises in
Dr Victoria Woodcock is a Consultant in Medical Oncology at Oxford University Hospitals NHS Trust, specialising in the treatment of colorectal cancer. She studied medicine at the University of Warwick, graduating in 2009, and went on to complete her specialist training in medical oncology in Oxford. In 2015, she was awarded a Cancer Research UK Clinical Trials Fellowship, during which she spent 18 months at the Oxford Early Phase Clinical Trials Unit, contributing to a range of early-phase trials across multiple cancer types. With a strong interest in immuno-oncology, Dr Woodcock undertook a DPhil in Oncology at the Weatherall Institute of Molecular Medicine, funded by Cancer Research UK. Her research focused on immune responses to checkpoint inhibitor therapy in patients with melanoma. Dr Woodcock has extensive experience in the use of chemotherapy, immunotherapy, and targeted therapies. Her main research interest lies in the development of new cancer treatments that enhance the immune response to tumours. She is Principal Investigator for several colorectal cancer trials and works closely with the Oxford Early Phase Clinical Trials Unit. She also serves as the clinical lead for the late-phase oncology clinical research team at the Churchill Hospital. |
Career positions
Current position(s)
- Consultant Medical Oncologist, GenesisCare Oxford
- Consultant in Medical Oncology at The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford.
Education
Current position(s)
- Medical and oncology training, Sydney University
- Fellowship in early phase clinical trials, Oxford
Professional memberships
- Royal College of Physicians
- Association of Cancer Physicians
- European Society for Medical Oncology (ESMO)
Awards
- Cancer Research UK Clinical Trials Fellowship
- CRUK Oxford Centre Clinical Research Training Fellowship
Publications & affiliations
Oxford Handbook of Oncology 5th edition, Oxford University Press. 2025
Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients. Melero et al. Annals of Oncology 2024
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer. VK Woodcock et al. BJUI compass 2023
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Middleton et al. Clin Cancer Res. 2020
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. VK Woodcock et al. British Journal of Cancer, 2018
Registered
GMC reference number: 07045747